Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Autoři	HANDELS Ron L. H. GREEN Colin GUSTAVSSON Anders HERRING William L. WINBLAD Bengt WIMO Anders SKOLDUNGER Anders KARLSSON Andreas ANDERSON Robert BELGER Mark BRUCK Chiara ESPINOSA Robert HLÁVKA Jakub JUTKOWITZ Eric LIN Pei-Jung MENDEZ Mauricio Lopez MAR Javier SHEWMAKER Peter SPACKMAN Eldon TAFAZZOLI Ali TYSINGER Bryan JONSSON Linus
Rok publikování	2023
Druh	Článek v odborném periodiku
Časopis / Zdroj	ALZHEIMERS & DEMENTIA
Citace
www	https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12811
Doi	http://dx.doi.org/10.1002/alz.12811
Klíčová slova	Alzheimer's disease; cross-comparison; decision-analytic modeling; dementia; economic evaluation; model validation
Popis	Introduction The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge. Methods Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop. Results A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia). Discussion The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.